local_hospital

A.O.U. Gaetano Martino

Address
Via Consolare Valeria, 98124 Messina, Italy

A.O.U. Gaetano Martino - Cardiovascular and Renal Disease Research

A.O.U. Gaetano Martino is a distinguished medical research center conducting advanced clinical investigations in cardiovascular interventions and renal disorders. The center demonstrates particular expertise in complex antithrombotic therapy strategies and chronic kidney disease management.

  • Antithrombotic therapy optimization in patients with atrial fibrillation undergoing percutaneous coronary intervention
  • Novel therapeutic approaches for Autosomal Dominant Polycystic Kidney Disease
  • Comparative effectiveness research in cardiovascular and renal disease management

The center's cardiovascular research focuses on balancing bleeding risk and thrombotic protection in high-risk patients requiring both anticoagulation for atrial fibrillation and antiplatelet therapy following coronary stent placement. In nephrology, the institution investigates alternative treatment strategies for ADPKD, comparing established vasopressin antagonist therapy with metabolic interventions using metformin to slow disease progression and preserve renal function. These trials reflect the center's commitment to improving clinical outcomes through evidence-based treatment optimization in complex patient populations.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
10
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
2
Sponsors (total)
2
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
2
Outperforms 36% of sites
public
Therapeutic diversity
2areas
Outperforms 41% of sites
groups
Sponsor diversity
2sponsors
Outperforms 37% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in A.O.U. Gaetano Martino

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 3a Randomized Controlled Trial Comparing Metformin and Tolvaptan in Adults with Autosomal Dominant Polycystic Kidney DiseaseUniversity Of Bari Aldo MoroPhase IIIRecruitingSep 2020

IMP list

lock Showing 1 of 10 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Acetylsalicylic Acid1Unknown2024-12-162024-12-16

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.